Skip to main content Accessibility help
×
Home

The interface between neurology and psychiatry: the case of multiple sclerosis

  • Eugene K. O. Wong, Rajeev Krishnadas and Jonathan Cavanagh
  • Please note an addendum has been issued for this article.

Summary

There has been a surge in interest in the boundaries of psychiatry, both as a specialty in its own right and as a branch of medicine separate from neurology. Our article expands on this, giving examples of how recent developments in neuroimmunology can be beneficial for psychiatry, using multiple sclerosis (MS) as an example. We also provide a summary of literature on novel research in the treatment of depression using anti-inflammatory agents. Finally, we suggest approaches to the identification and management of major depressive disorder in patients with MS or other physical illnesses, and how this translates to general psychiatric practice.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The interface between neurology and psychiatry: the case of multiple sclerosis
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The interface between neurology and psychiatry: the case of multiple sclerosis
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The interface between neurology and psychiatry: the case of multiple sclerosis
      Available formats
      ×

Copyright

Corresponding author

Dr Eugene K. O. Wong, Anvil Centre, Parkhead Hospital, 81 Salamanca Street, Glasgow G31 5ES, UK. Email: eugene.wongs@gmail.com

Footnotes

Hide All

Declaration of Interest

J. C. has received grants from Biogen and Pfizer.

Footnotes

References

Hide All
Alonso, A, Hernan, MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71: 129–35.
Arnason, BG (2009) Multiple sclerosis and depression: a neuroimmunological perspective. In The Brain and Host Defense (Neuro-Immune Biology, vol 9) (ed Arnason, BG) 269-307. Elsevier.
Barry, H, Hardiman, O, Healy, DG et al (2011) Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. British Journal of Psychiatry 199: 508–9.
Brunello, N, Alboni, S, Capone, G et al (2006) Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. International Clinical Psychopharmacology 21: 219–25.
Byatt, N, Rothschild, AJ, Riskind, P et al (2011) Relationships between multiple sclerosis and depression. Journal of Neuropsychiatry & Clinical Neurosciences 23: 198-200.
Capuron, L, Gumnick, JF, Musselman, DL et al (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26: 643–52.
Capuron, L, Miller, AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacology & Therapeutics 130: 226–38.
Cavanagh, J, Paterson, C, McLean, J et al (2010) Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study. Annals of the Rheumatic Diseases 69: 1251–2.
Charcot, J (1877) Lectures on Diseases of the Nervous System. New Sydenham Society.
Crawford, JD, McIvor, GP (1985) Group psychotherapy: benefits in multiple sclerosis. Archives of Physical Medicine and Rehabilitation 66: 810–3.
D'Alisa, S, Miscio, G, Baudo, S et al (2006) Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disability and Rehabilitation 28: 307–14.
Dickens, C, McGowan, L, Clark-Carter, D et al (2002) Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosomatic Medicine 64: 52-60.
Foley, FW, Bedell, JR, LaRocca, NG et al (1987) Efficacy of stress-inoculation training in coping with multiple sclerosis. Journal of Consulting and Clinical Psychology 55: 919–22.
Foley, FW, Traugott, U, LaRocca, NG et al (1992) A prospective study of depression and immune dysregulation in multiple sclerosis. Archives of Neurology 49: 238–44.
Ghaffar, O, Feinstein, A (2007) The neuropsychiatry of multiple sclerosis: a review of recent developments. Current Opinion in Psychiatry 20: 278–85.
Gold, SM, Raji, A, Huitinga, I et al (2005) Hypothalamo–pituitary–adrenal axis activity predicts disease progression in multiple sclerosis. Journal of Neuroimmunology 165: 186–91.
Goldman Consensus Group (2005) The Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis 11: 328–37.
Gowers, WR (1893) A Manual of Diseases of the Nervous System (Reprinted 1970). Hafner.
Hackett, ML, Anderson, CS (2005) Predictors of depression after stroke: a systematic review of observational studies. Stroke 36: 2296–301.
Holsboer, F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
Kahl, KG, Kruse, N, Faller, H et al (2002) Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 27: 671–81.
Kandel, ER (1998) A new intellectual framework for psychiatry. American Journal of Psychiatry 155: 457–69.
Koch, MW, Glazenborg, A, Uyttenboogaart, M et al (2011) Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database of Systematic Reviews 2: CD007295.
Krishnadas, R (2010) Etanercept for sleep in patients with alcohol use disorder – mechanisms need to be elucidated. Biological Psychiatry 67: e1.
Krishnadas, R, Cavanagh, J (2011) Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: a case report and review of the literature. Journal of Medical Case Reports 5: 112.
Krishnadas, R, Cavanagh, J (2012) Depression: an inflammatory illness? Journal of Neurology, Neurosurgery & Psychiatry 83: 495-502.
Kroencke, DC, Denney, DR, Lynch, SG (2001) Depression during exacerbations in multiple sclerosis: the importance of uncertainty. Multiple Sclerosis 7: 237–42.
Larcombe, NA, Wilson, PH (1984) An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. British Journal of Psychiatry 145: 366–71.
Lennox, BR, Coles, AJ, Vincent, A (2012) Antibody-mediated encephalitis: a treatable cause of schizophrenia. British Journal of Psychiatry 200: 92–4.
Lo Fermo, S, Barone, R, Patti, F et al (2010) Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Multiple Sclerosis 16: 742–8.
Luzzio, C (2011) Multiple sclerosis clinical presentation. Medscape Reference (http://emedicine.medscape.com/article/1146199-clinical). Accessed 11 May 2013.
Maes, M (1999) Major depression and activation of the inflammatory response system. Advances in Experimental Medicine and Biology 461: 25-46.
Messmer Uccelli, M, Mancuso Mohr, L, Battaglia, MA et al (2004) Peer support groups in multiple sclerosis: current effectiveness and future directions. Multiple Sclerosis 10: 80–4.
Miller, AH, Pariante, CM, Pearce, BD (1999) Effects of cytokines on glucocorticoid receptor expression and function: glucocorticoid resistance and relevance to depression. Advances in Experimental Medicine and Biology 461: 107–16.
Mohr, DC, Goodkin, DE, Gatto, N et al (1997) Depression, coping and level of neurological impairment in multiple sclerosis. Multiple Sclerosis 3: 254–8.
Mohr, DC, Cox, D (2001) Multiple sclerosis: empirical literature for the clinical health psychologist. Journal of Clinical Psychology 57: 479–99.
Mohr, DC, Genain, C (2004) Social support as a buffer in the relationship between treatment for depression and T-cell production of interferon gamma in patients with multiple sclerosis. Journal of Psychosomatic Research 57: 155–8.
Mohr, DC, Pelletier, D (2006) A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain, Behavior, and Immunity 20: 27-36.
Möller, A, Wiedemann, G, Rohde, U et al (1994) Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatrica Scandinavica 89: 117–21.
Müller, N, Schwarz, MJ, Dehning, S et al (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 11: 680–4.
National Collaborating Centre for Mental Health (2009) Depression in Adults with a Chronic Physical Health Problem: Treatment and Management (NICE Clinical Guideline 91). National Institute for Health and Clinical Excellence.
National Institute for Health and Clinical Excellence (2009) Depression in Adults: The treatment and Management of Depression in Adults (Update) (NICE Clinical Guideline 90). NICE.
O'Connor, KC, Bar-Or, A, Hafler, DA (2001) The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. Journal of Clinical Immunology 21: 81-92.
Oyebode, F, Humphreys, M (2011) The future of psychiatry. British Journal of Psychiatry 199: 439–40.
Pasco, JA, Jacka, FN, Williams, LJ et al (2010) Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychotherapy and Psychosomatics 79: 323–5.
Qin, L, Wu, X, Block, ML, Liu, Y et al (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453–62.
Rosati, G (2001) The prevalence of multiple sclerosis in the world: an update. Neurological Sciences 22: 117–39.
Schiepers, OJ, Wichers, MC, Maes, M (2005) Cytokines and major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29: 201–17.
Schiffer, RB, Babigian, HM (1984) Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis. An epidemiologic study. Archives of Neurology 41: 1067–9.
Simpson, S Jr., Blizzard, L, Otahal, P et al (2011) Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry 82: 1132–41.
Thomas, PW, Thomas, S, Hillier, C et al (2006) Psychological interventions for multiple sclerosis. Cochrane Database of Systematic Reviews 1: CD004431.
Turnbull, AV, Rivier, CL (1999) Regulation of the hypothalamic–pituitary–adrenal axis by cytokines: actions and mechanisms of action. Physiological Reviews 79: 1-71.
Webster, MJ, Knable, MB, O'Grady, J et al (2002) Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry 7: 985–94.
Wichers, MC, Maes, M (2004) The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. Journal of Psychiatry and Neuroscience 29: 11–7.
Wong, EKO (2013) Borderline personality disorder in the east. Asian Journal of Psychiatry 6: 80–1.
Yang, CC, Jick, SS, Jick, H (2003) Lipid-lowering drugs and the risk of depression and suicidal behavior. Archives of Internal Medicine 163: 1926–32.
Young, EA, Haskett, RF, Murphy-Weinberg, V et al (1991) Loss of glucocorticoid fast feedback in depression. Archives of General Psychiatry 48: 693–9.
Young-Xu, Y, Chan, KA, Liao, JK et al (2003) Long-term statin use and psychological well-being. Journal of the American College of Cardiology 42: 690–7.

The interface between neurology and psychiatry: the case of multiple sclerosis

  • Eugene K. O. Wong, Rajeev Krishnadas and Jonathan Cavanagh
  • Please note an addendum has been issued for this article.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

The interface between neurology and psychiatry: the case of multiple sclerosis

  • Eugene K. O. Wong, Rajeev Krishnadas and Jonathan Cavanagh
  • Please note an addendum has been issued for this article.
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *



An addendum has published for this article: